<DOC>
	<DOCNO>NCT02195869</DOCNO>
	<brief_summary>The purpose study assess safety clinical efficacy ibrutinib subject steroid dependent refractory Chronic Graft Versus Host Disease .</brief_summary>
	<brief_title>Study Bruton 's Tyrosine Kinase Inhibitor Subjects With Chronic Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Steroid dependent refractory classic chronic GVHD disease . No 3 previous treatment cGVHD . Receiving baseline systemic glucocorticoid therapy ( stable dose ) cGVHD study entry . Men woman ≥18 year old . Karnofsky performance status ≥60 . Known suspect active acute GVHD . Current treatment sirolimus AND either cyclosporine tacrolimus . History treatment tyrosine kinase inhibitor ( eg , imatinib ) , purine analog cancer chemotherapy 4 week prior start study drug . Currently active , clinically significant cardiovascular disease . Uncontrolled infection responsive antibiotic , antiviral medicine , antifungal medicine recent infection require systemic treatment complete ≤14 day first dose study drug . Progressive underlying malignant disease include posttransplant lymphoproliferative disease . History malignancy ( include underlie malignancy indication transplant ) Concomitant use warfarin Vitamin K antagonists Known bleed disorder hemophilia . History stroke intracranial hemorrhage within 6 month prior enrollment . Known history human immunodeficiency virus ( HIV ) active hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) . Concurrent use strong cytochrome P450 ( CYP ) 3A inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PCYC1129</keyword>
	<keyword>PCYC1129CA</keyword>
	<keyword>1129</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>PCI32765</keyword>
	<keyword>IMBRUVICA</keyword>
	<keyword>Pharmacyclics</keyword>
	<keyword>PCYC</keyword>
	<keyword>GVHD</keyword>
	<keyword>Steroid dependent</keyword>
	<keyword>refractory</keyword>
	<keyword>chronic</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>chronic graft versus host disease</keyword>
	<keyword>immunology</keyword>
</DOC>